Weight decline in patients switching from olanzapine to quetiapine

Sanjay Gupta, Prakash S. Masand, Shubdeep Virk, Thomas Schwartz, Ahmed Hameed, Bradford L. Frank, Kari Lockwood

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

This open-label study investigated the strategy of switching patients who had gained excessive weight on olanzapine to quetiapine, with assessments of safety and continued efficacy as well as weight change. Patients who were psychiatrically stable on olanzapine but had gained >20% in weight and had body mass index >25 mg/kg2 were switched to quetiapine over a 4-week period and followed for 6 weeks, the total study duration being 10 weeks. Assessments included weight change, antipsychotic efficacy using the Positive and Negative Symptom Syndrome Scale (PANSS), extrapyramidal adverse events using the Simpson-Angus Scale (SAS), and laboratory studies for metabolic measures. Of 16 enrolled patients, 12 completed the study. Mean weight loss was 2.25 kg (Cohen's d=0.12; P=0.03). There were no significant changes in PANSS total scores, SAS scores, or metabolic parameters. Switching patients to quetiapine, appears to be a viable strategy for managing olanzapine-induced weight gain as indicated by this 10-week open-label study. Prospective controlled trials of longer duration and larger number of subjects are needed.

Original languageEnglish (US)
Pages (from-to)57-62
Number of pages6
JournalSchizophrenia Research
Volume70
Issue number1
DOIs
StatePublished - Sep 1 2004

Fingerprint

olanzapine
Weights and Measures
Antipsychotic Agents
Weight Gain
Weight Loss
Body Mass Index
Safety
Quetiapine Fumarate

All Science Journal Classification (ASJC) codes

  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this

Gupta, S., Masand, P. S., Virk, S., Schwartz, T., Hameed, A., Frank, B. L., & Lockwood, K. (2004). Weight decline in patients switching from olanzapine to quetiapine. Schizophrenia Research, 70(1), 57-62. https://doi.org/10.1016/j.schres.2003.09.016
Gupta, Sanjay ; Masand, Prakash S. ; Virk, Shubdeep ; Schwartz, Thomas ; Hameed, Ahmed ; Frank, Bradford L. ; Lockwood, Kari. / Weight decline in patients switching from olanzapine to quetiapine. In: Schizophrenia Research. 2004 ; Vol. 70, No. 1. pp. 57-62.
@article{553ede1a599f4b01b5870213e1761e07,
title = "Weight decline in patients switching from olanzapine to quetiapine",
abstract = "This open-label study investigated the strategy of switching patients who had gained excessive weight on olanzapine to quetiapine, with assessments of safety and continued efficacy as well as weight change. Patients who were psychiatrically stable on olanzapine but had gained >20{\%} in weight and had body mass index >25 mg/kg2 were switched to quetiapine over a 4-week period and followed for 6 weeks, the total study duration being 10 weeks. Assessments included weight change, antipsychotic efficacy using the Positive and Negative Symptom Syndrome Scale (PANSS), extrapyramidal adverse events using the Simpson-Angus Scale (SAS), and laboratory studies for metabolic measures. Of 16 enrolled patients, 12 completed the study. Mean weight loss was 2.25 kg (Cohen's d=0.12; P=0.03). There were no significant changes in PANSS total scores, SAS scores, or metabolic parameters. Switching patients to quetiapine, appears to be a viable strategy for managing olanzapine-induced weight gain as indicated by this 10-week open-label study. Prospective controlled trials of longer duration and larger number of subjects are needed.",
author = "Sanjay Gupta and Masand, {Prakash S.} and Shubdeep Virk and Thomas Schwartz and Ahmed Hameed and Frank, {Bradford L.} and Kari Lockwood",
year = "2004",
month = "9",
day = "1",
doi = "10.1016/j.schres.2003.09.016",
language = "English (US)",
volume = "70",
pages = "57--62",
journal = "Schizophrenia Research",
issn = "0920-9964",
publisher = "Elsevier",
number = "1",

}

Gupta, S, Masand, PS, Virk, S, Schwartz, T, Hameed, A, Frank, BL & Lockwood, K 2004, 'Weight decline in patients switching from olanzapine to quetiapine', Schizophrenia Research, vol. 70, no. 1, pp. 57-62. https://doi.org/10.1016/j.schres.2003.09.016

Weight decline in patients switching from olanzapine to quetiapine. / Gupta, Sanjay; Masand, Prakash S.; Virk, Shubdeep; Schwartz, Thomas; Hameed, Ahmed; Frank, Bradford L.; Lockwood, Kari.

In: Schizophrenia Research, Vol. 70, No. 1, 01.09.2004, p. 57-62.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Weight decline in patients switching from olanzapine to quetiapine

AU - Gupta, Sanjay

AU - Masand, Prakash S.

AU - Virk, Shubdeep

AU - Schwartz, Thomas

AU - Hameed, Ahmed

AU - Frank, Bradford L.

AU - Lockwood, Kari

PY - 2004/9/1

Y1 - 2004/9/1

N2 - This open-label study investigated the strategy of switching patients who had gained excessive weight on olanzapine to quetiapine, with assessments of safety and continued efficacy as well as weight change. Patients who were psychiatrically stable on olanzapine but had gained >20% in weight and had body mass index >25 mg/kg2 were switched to quetiapine over a 4-week period and followed for 6 weeks, the total study duration being 10 weeks. Assessments included weight change, antipsychotic efficacy using the Positive and Negative Symptom Syndrome Scale (PANSS), extrapyramidal adverse events using the Simpson-Angus Scale (SAS), and laboratory studies for metabolic measures. Of 16 enrolled patients, 12 completed the study. Mean weight loss was 2.25 kg (Cohen's d=0.12; P=0.03). There were no significant changes in PANSS total scores, SAS scores, or metabolic parameters. Switching patients to quetiapine, appears to be a viable strategy for managing olanzapine-induced weight gain as indicated by this 10-week open-label study. Prospective controlled trials of longer duration and larger number of subjects are needed.

AB - This open-label study investigated the strategy of switching patients who had gained excessive weight on olanzapine to quetiapine, with assessments of safety and continued efficacy as well as weight change. Patients who were psychiatrically stable on olanzapine but had gained >20% in weight and had body mass index >25 mg/kg2 were switched to quetiapine over a 4-week period and followed for 6 weeks, the total study duration being 10 weeks. Assessments included weight change, antipsychotic efficacy using the Positive and Negative Symptom Syndrome Scale (PANSS), extrapyramidal adverse events using the Simpson-Angus Scale (SAS), and laboratory studies for metabolic measures. Of 16 enrolled patients, 12 completed the study. Mean weight loss was 2.25 kg (Cohen's d=0.12; P=0.03). There were no significant changes in PANSS total scores, SAS scores, or metabolic parameters. Switching patients to quetiapine, appears to be a viable strategy for managing olanzapine-induced weight gain as indicated by this 10-week open-label study. Prospective controlled trials of longer duration and larger number of subjects are needed.

UR - http://www.scopus.com/inward/record.url?scp=3142756414&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3142756414&partnerID=8YFLogxK

U2 - 10.1016/j.schres.2003.09.016

DO - 10.1016/j.schres.2003.09.016

M3 - Article

C2 - 15246464

AN - SCOPUS:3142756414

VL - 70

SP - 57

EP - 62

JO - Schizophrenia Research

JF - Schizophrenia Research

SN - 0920-9964

IS - 1

ER -